BMS shareholders approve Celgene megadeal

Bristol-Myers Squibb shareholders approved the company ’s $74 billion acquisition of rival Celgene, despite activist campaigns to break up the deal.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news